Lunai Bioworks Inc. - Asset Resilience Ratio
Lunai Bioworks Inc. (LNAI) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Lunai Bioworks Inc. carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Lunai Bioworks Inc.'s Asset Resilience Ratio has changed over time. See Lunai Bioworks Inc. (LNAI) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Lunai Bioworks Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LNAI market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Lunai Bioworks Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Lunai Bioworks Inc. Industry Peers by Asset Resilience Ratio
Compare Lunai Bioworks Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT |
Biotechnology | 63.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bio-Thera Solutions Ltd
SHG:688177 |
Biotechnology | 4.09% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Gubra A/S
CO:GUBRA |
Biotechnology | 79.61% |
Annual Asset Resilience Ratio for Lunai Bioworks Inc. (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Lunai Bioworks Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 4.71% | $387.85K | $8.23 Million | -- |
| 2024-06-30 | 0.00% | $0.00 | $163.13 Million | -- |
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more